One study reported high expression of JCAD in multiple hepatoma cell lines and in pre-carcinoma lesions in a mouse model of non-alcoholic steatohepatitis (NASH), as well as in human NASH-associated hepatocellular carcinoma, in contrast to the low levels of expression in normal human liver [8]. Here, JCAD is linked to metabolic dysfunction-associated steatohepatitis.